The field of biofabrication develops applications aimed at personalized medicine. Tissue engineering associated with bioprinting makes possible solutions such as the development of cultured meat as well as of advanced therapies aimed at replacing human organs.
Pharmaceutical and cosmetic industry
The major challenge for the pharmaceutical and cosmetics industry is to find alternatives and solutions for pre-clinical testing of drugs and formulations before they are released to the market.
There are no good preclinical models that say that a new drug is effective and safe to move on to clinical trials. The use of animal models is increasingly contradictory, since these trials deal with ethical issues, as well as high cost and do not provide much relevance for the assessment of human risk.
In addition, there is a growing idea that in vitro approaches can eliminate these problems without jeopardizing human security, due to the repeatability standards that bio printers allow to achieve.
3D bioprinting has caused enthusiasm in the field of regenerative medicine. The prospect is that in the medium term, 5 to 10 years, it will be possible to deliver printed tissues to surgeons that meet specific demands, from skin, cartilage, bone, to vascular grafts and more complex organs.
The flexibility of our bioprinting technology makes it possible to use a wide variety of cells and materials, making it possible to build tissues from allogeneic cells, which are not the patient’s or autogenous cells, from the patient himself, thus reducing rejections and the need for drugs immunosuppressive.